Levetiracetam Aurovitas (Levetiracetam)

Levetiracetam exerts its effect by binding to the synaptic vesicle protein SV2A, which plays a crucial role in the regulation of neurotransmitter release. This binding modulates the release of excitatory neurotransmitters such as glutamate, stabilizing neuronal activity and reducing the hyper‑excitability that leads to seizure generation.

The dosage of Levetiracetam Aurovitas is individualized and set by the prescribing physician based on factors such as the patient’s age, weight, renal function, seizure type, and response to therapy. No fixed regimen is provided here; clinicians adjust the dose to achieve optimal seizure control while minimizing adverse effects.

Safety of levetiracetam during pregnancy and lactation has not been fully established. The decision to use the product in pregnant or nursing women should be made after careful consideration of the potential benefits versus risks, and in consultation with a healthcare professional experienced in managing epilepsy in these populations.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Levetiracetam Aurovitas. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After the request, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Levetiracetam differs from many traditional antiepileptics such as valproic acid or carbamazepine in that it has a unique mechanism involving SV2A binding and does not significantly affect hepatic enzyme systems. This often results in a lower potential for drug‑drug interactions, a more favorable side‑effect profile, and easier dose titration, making it a valuable option for patients who have experienced adverse effects with other agents.

Levetiracetam Aurovitas must be stored refrigerated at 2‑8 °C. The solution should be kept in its original container, protected from light, and must not be frozen or shaken. If the product is removed from refrigeration, it should be used within the time frame specified by the manufacturer to maintain stability and potency.

The medication is supplied as an intravenous solution and is administered by a qualified healthcare professional through a controlled IV infusion. The infusion rate and duration are determined by the prescribing clinician, taking into account the patient’s clinical status and any concurrent therapies. Monitoring during and after infusion is recommended to detect any immediate adverse reactions.

Serious risks, although uncommon, include severe allergic reactions such as anaphylaxis, the emergence of suicidal thoughts or behaviors, and hepatic dysfunction indicated by abnormal liver enzymes or jaundice. Patients should be monitored for any signs of rash, mood changes, or liver-related symptoms, and immediate medical attention should be sought if these occur.

Levetiracetam Aurovitas is contraindicated in individuals with known hypersensitivity to levetiracetam or any component of the formulation. Caution is also advised for patients with severe renal impairment who may require dose adjustment, and for those with a history of serious psychiatric disorders, as the medication may exacerbate mood changes.